April 11, 2012
Medidata Balance now offers multiple randomization methodologies to further drive efficiencies and reduce costs of study start-up
NEW YORK, April 11 — Medidata Solutions announced today a major new release of Medidata Balance, a randomization and trial supply management (RTSM) application which is part of Medidata's comprehensive clinical cloud platform. Balance now provides the popular block randomization methodology in addition to the powerful and flexible dynamic allocation methodology it previously offered. These two methodologies cover the large majority of the range of developers' requirements for randomly allocated clinical trials.
Sponsors use randomization technology to assign newly enrolled patients to a treatment group. Appropriate randomization methodology is critical to ensuring statistical validity and can also affect the required number of enrolled patients. Drug development teams now have the flexibility to choose the most frequently used randomization methodologies while leveraging the key features of the cloud-based Balance, including guided user setup and simulation capabilities, and built-in integration with the Medidata Rave system for electronic data capture (EDC) and clinical data management (CDM).
With intuitive, configurable capabilities for designing the randomization plan, Balance offers sponsors built-in simulation to test the quality of the balance achieved across the sites, strata and factors, as well as the entire study. With Balance's new permuted block capability, the simulator can also be used to compare randomization results of dynamic allocation against block, offering sponsors a new level of visibility in trial planning.
Once the design for the study is complete and trial operations have begun, all randomization and treatment dispensation instructions are sent to investigative site staff through the Medidata Rave platform using a single browser interface. With Balance, site staff can access one integrated, easy-to-use system to enroll subjects in treatment arms, receive treatment instructions and capture patient data.
Connect with Medidata:
About Medidata Solutions Worldwide
Medidata Solutions (NASDAQ: MDSO) is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.
Source: Medidata Solutions Worldwide
10/30/2013 | Cray, DDN, Mellanox, NetApp, ScaleMP, Supermicro, Xyratex | Creating data is easy… the challenge is getting it to the right place to make use of it. This paper discusses fresh solutions that can directly increase I/O efficiency, and the applications of these solutions to current, and new technology infrastructures.
10/01/2013 | IBM | A new trend is developing in the HPC space that is also affecting enterprise computing productivity with the arrival of “ultra-dense” hyper-scale servers.
Ken Claffey, SVP and General Manager at Xyratex, presents ClusterStor at the Vendor Showdown at ISC13 in Leipzig, Germany.
Join HPCwire Editor Nicole Hemsoth and Dr. David Bader from Georgia Tech as they take center stage on opening night at Atlanta's first Big Data Kick Off Week, filmed in front of a live audience. Nicole and David look at the evolution of HPC, today's big data challenges, discuss real world solutions, and reveal their predictions. Exactly what does the future holds for HPC?